The Relationship Between Late Morbidity and Dose–Volume Parameter of Rectum in Combined Intracavitary/Interstitial Cervix Cancer Brachytherapy: A Mono-Institutional Experience

Ning Zhang, Ying Liu, Dongmei Han, Xin Guo, Zhuang Mao, Wei Yang and Guanghui Cheng*

Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, China

Purpose: To establish a dose volume–effect relationship for predicting late rectal complication (LRC) in locally advanced cervical cancer patients treated with external beam radiotherapy (EBRT) followed by combined intracavitary/interstitial brachytherapy (IC/IS-BT).

Materials and Methods: A retrospective analysis was performed in 110 patients with locally advanced cervical cancer who underwent definitive radiotherapy combined with IC/IS-BT from July 2010 to September 2018. We report the 90% of the target volume receiving the minimum dose for high risk clinical target volume (HR-CTV D90) and intermediate risk clinical target volume (IR-CTV D90), and the minimum doses to the most exposed 0.1, 1, and 2 cm³ D1cm³, D1cm³, D2cm³ doses at the International Commission on Radiation Units and Measurements (DICRU) for organs at risk (OARs). The total dose of EBRT plus brachytherapy was transformed to the biologically equivalent dose in 2 Gy fractions (EQD2) with α/β value of 10 Gy for target, 3 Gy for organs at risk using the linear quadratic model. The morbidity was scored according to the Radiation Therapy Oncology Group (RTOG) criteria. The Probit model was used to establish a prediction model on rectum between the organs at risk for dose and LRC. The receiver operating characteristic (ROC) curve was used to evaluate the predictive value of dose volume parameters for LRC.

Results: The median follow-up time was 72.3 months. The mean (± standard deviation) D2cm³, D1cm³, D0.1cm³, and DDICRU values of rectum were 64.72 ± 7.47 GyEQD2, 70.18 ± 5.92 GyEQD2, 79.32 ± 7.86 GyEQD2, and 67.22 ± 7.87 GyEQD2, respectively. The Probit model showed significant relationships between D1cm³ or D0.1cm³, and the probability of grade1–4, grade 2–4 rectal events at 1 year, and between D1cm³and the probability of grade2–4 rectal events at 3 and 5 years. The dose values for 10% complication rates (ED10) of D1cm³ were 74.18 (70.42–76.71) GyEQD2, 67.80 (59.91, 71.08) GyEQD2, 66.37 (52.00, 70.27) GyEQD2 for grade 2–4 with rectal morbidity at 1, 3, and 5 years, respectively.
Conclusion: Our study proved that $D_{1cm^3}$ and $D_{0.1cm^3}$ were considered as useful dosimetric parameters for predicting the risk of grade 1–4 and grade 2–4 LRC at 1 year, and $D_{1cm^3}$ might be an indicator for predicting grade 2–4 LRC at 3/5 years. The patients with rectal $D_{1cm^3} > 66.37–74.18$ Gy$_{EQD2}$ should be closely observed for grade 2–4 LRC.

Keywords: dose–effect relationship, late rectal complication, cervical cancer, brachytherapy, intracavitary/interstitial brachytherapy

INTRODUCTION

Brachytherapy is a crucial component of radical radiotherapy of locally advanced cervical cancer (1), and it mainly includes intracavitary brachytherapy (ICBT), interstitial brachytherapy (ISBT), and hybrid intracavitary/interstitial brachytherapy (IC/IS-BT). The IC/IS-BT approach allows placement of interstitial needles for better coverage of large or asymmetric tumors, delivering a high dose to the target region while sparing the OARs. During brachytherapy, the rectum is one of the most important parts for dose constraints for OARs. It may be helpful to find out a sensitive indicator in dosimetric parameters for rectal assessment of dose to avoid late rectal complication (LRC). Several studies have reported a statistically significant correlation between $D_{2cm^3}$ and occurrence of LRC in cervical cancer patients who had brachytherapy (2, 3). Meanwhile, several other studies found other dosimetric parameters, such as $D_{1cm^3}$ or $D_{ICRU}$, also exhibited a statistically significant relationship (4, 5). However, few studies have compared the differences in rectal dosimetric parameters, while very few lacked a more reliable prediction model. Hence, in the present study, the role of three-dimensional dosimetric parameters $D_{2cm^3}$, $D_{1cm^3}$, $D_{0.1cm^3}$, and two-dimensional dosimetric parameter $D_{ICRU}$ in the prediction of LRC were analyzed and compared, and relevant models for locally advanced cervical cancer treatment with curative radiotherapy including IC/IS-BT were established.

MATERIALS AND METHODS

Patients

A total of 110 patients with locally advanced cervical cancer who visited our hospital and underwent definitive chemoradiotherapy combined with IC/IS-BT were enrolled from July 2010 to September 2018. Most of the patients (94.5%) had squamous cell carcinoma, and the remaining patients had adenocarcinoma (3.64%) or other carcinomas (1.86%). The age of the patients ranged between 23 and 84 years; the mean age at initial treatment was 53.98 ± 10.97. According to 2009 FIGO stage, 6 patients were in IB2, 20 were in IIA2, 59 were in IIB, 8 were in IIIA, 14 were in IIIB, and 3 were in IVA.

Treatment Procedure

All patients completed external beam radiotherapy with 43.2–55.8 Gy for 25–31 fractions of 1.8–2.0 Gy with or without platinum-based chemotherapy followed by IC/IS-BT with 14–28 Gy for 2–4 fractions, 7 Gy one fraction. Eighty-eight patients underwent EBRT technique with IMRT, and the remaining 22 patients completed with 3D-CRT technique. In addition, patient and tumor characteristics and radiotherapy regimen are shown in Supplementary Table 1.

IC/IS-BT was based on MRI/CT, and the MRI was performed separately before external beam radiotherapy (EBRT) and brachytherapy treatment. The applicator insertion was done under general anesthesia in an operating room. The applicators, including the Utrecht applicator combined with interstitial technique, Vienna applicator for combined IC/IS-BT, and the multi-channel vaginal applicator, were used in most of the patients. In patients with advanced stage IIIB, parametral implants could be added in addition to a standard applicator.

Data Collection and Evaluation Criteria

According to GYN GEC ESTRO recommendations (6) and Dimopoulos et al. (7) the gross tumor volume (GTV), two clinical target volumes (CTVs, high risk CTVs, intermediate risk CTVs), and outer walls of OARs were delineated based on MRI or CT images. The OARs included the rectum, bladder, sigmoid colon, and small intestine. The target volume and OARs were contoured by one gynecologic doctor then evaluated by two senior gynecologic oncologists in this research, and the doctors took extra care with the rectal contouring. Target volume parameters $D_{90}$ and $D_{90}$ of HR-CTV, IR-CTV were tabulated. $D_{2cm^3}$, $D_{1cm^3}$, $D_{0.1cm^3}$, and $D_{ICRU}$ were tabulated for OARs.

For dose evaluation, the dose calculation was performed using the linear quadratic model with $\alpha/\beta = 10$ Gy for the tumor target, and $\alpha/\beta = 3$ Gy for the OARs, and then converted into the equivalent dose in 2 Gy fractions (EQD2). Total dose evaluation for the CTVs and OARs was the total EQD2 value of the dose from BT accumulated with the dose of EBRT. The goal of combined EBRT and BT was to achieve a total dose $\geq 85$ Gy of HR-CTV $D_{90}$ and a constraint of 85 Gy for the bladder and 70 Gy for the rectum, sigmoid, and bowel.

Follow-Up

After treatment, all patients were followed up once every 3 months in the first 2 years and once every half a year thereafter. Follow-up evaluation consisted of local recurrence, distant metastasis, survival, etc. Late side effects were graded according to the toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) (8). CT/MRI of the pelvis or PET scans were performed once or twice a year according to the specific conditions of these patients.
**Statistical Analysis**

The continuous variables were presented as means ± standard deviation (X±S), and the categorical variables were presented as counts or percentages (%). A Probit regression model was used to investigate the relationships between D_{2cm³}, D_{1cm³}, D_{0.1cm³}, D_{ICRU} and late side effects of rectum, and the receiver operating characteristic (ROC) curve was used to evaluate and compare the predictive values. All statistical analysis was two-sided and performed using SPSS 22.0 software (IBM, Armonk, NY, USA) and Stata 15.0 software (StataCorp LLC, Texas, USA). The EpiData 3.10 software (EpiData Association, Odense M, Denmark) was used for data entry and database establishment.

**RESULTS**

**Patient Characteristics**

Brachytherapy was conducted for a total of 438 times. The average number of needles per fraction was 3.78 (range 1–8), and the average depth was 3.12 cm. The D_{2cm³}, D_{1cm³}, D_{0.1cm³}, and D_{ICRU} for rectum, HR-CTV D₉₀, and IR-CTV D₉₀ are presented in **Table 1**. In addition, 17 cases of the 110 patients with cervical cancer did not receive chemotherapy, 21 cases received neoadjuvant chemotherapy before radiotherapy, 34 cases received concurrent chemotherapy, 1 case received adjuvant chemotherapy after radiotherapy, 25 cases received neoadjuvant chemotherapy combined with concurrent chemotherapy, 9 cases received concurrent chemotherapy combined with adjuvant chemotherapy, and 3 cases received neoadjuvant chemotherapy combined with concurrent chemotherapy and adjuvant chemotherapy. All chemotherapy regimens were platinum based. Other characteristic information and clinical outcomes have been previously published in scholarly journals (9).

**Tumor Response**

The criteria for evaluation of posttreatment efficacy were based on the revision of Response Evaluation Criteria for Solid Tumors published in 2009 (RECIST 1.1). The treatment efficacy of those 110 patients was assessed after radiotherapy, in which 72 (65.45%) cases achieved complete response (CR), 36 (32.73%) cases achieved partial response (PR), 1 (0.91%) case achieved progressive disease (PD), and 1 (0.91%) case achieved stable disease (SD).

**Incidence of Late Rectum Morbidity**

The median follow-up time was 72.3 months. The incidence of late rectum morbidity in patients with locally advanced cervical cancer is presented in **Figure 1** and **Table 2**. The 1-, 3-, and 5-year incidence of rectum morbidity with grade 1–4 was 12.7, 30.0, and 31.8%, respectively. The 1-, 3-, and 5-year incidence of rectum morbidity with grade 2–4 was 8.2, 17.3, and 18.2%, respectively.

**Dose of OARs for Predicting the Toxicity Morbidity**

The Probit model was used to establish the prediction models between D_{2cm³}, D_{1cm³}, D_{0.1cm³}, and D_{ICRU} for rectum and the 1-, 3-, and 5-year toxicity morbidities. Results clearly highlighted significant association of the D_{0.1cm³} of rectum with 1- or 3- or 5-year incidence of rectum morbidity with grade 1–4 or grade 2–4, and also revealed a significant relationship between D_{0.1cm³} of rectum and 1-year incidence of rectum morbidity with grade 1–4 or grade 2–4. The specific findings were as follows.

The 1-year incidence of rectum morbidity with grade 1–4 showed statistically significant relationship with D_{1cm³} and D_{0.1cm³}.

---

**TABLE 1 | DVH parameters for HR-CTV and OARs.**

| DVH parameters | X±S (GyEQD2) |
|----------------|-------------|
| HR-CTV D₉₀     | 91.28 ± 8.63 |
| IR-CTV D₉₀     | 68.47 ± 3.79 |
| Bladder D_{2cm³} | 77.20 ± 7.04 |
| Bladder D_{1cm³} | 82.36 ± 6.42 |
| Bladder D_{0.1cm³} | 95.98 ± 9.29 |
| Bladder D_{ICRU} | 76.72 ± 11.48 |
| Rectum D_{2cm³} | 64.72 ± 7.47 |
| Rectum D_{1cm³} | 70.18 ± 5.92 |
| Rectum D_{0.1cm³} | 79.32 ± 7.86 |
| Rectum D_{ICRU} | 67.22 ± 7.87 |

DVH, dose volume histogram; HR-CTV, high risk clinical target volume; IR-CTV, intermediate risk clinical target volume; D₀₉₀, the minimum dose delivered to 90% of the target volume; D₂cm³, D₁cm³, D₀.₁cm³, minimal dose to the maximally exposed 2 cm³, 1 cm³, 0.1 cm³ of organs at risk, respectively. D_{ICRU}, dose delivered to the International Commission for Radiation Units and Measurements (ICRU) point.

**TABLE 2 | The incidence of late rectum and bladder morbidity in patients with locally advanced cervical cancer at 1/3/5 years.**

| RTOG | G0 | G1 | G2 | G3 | G4 |
|------|----|----|----|----|----|
| 1 year Rectum | 96(87.3) | 5(4.5) | 3(2.7) | 6(5.5) | 0(0) |
| 3 years Rectum | 77(70.0) | 14(12.7) | 9(8.2) | 9(8.2) | 1(0.9) |
| 5 years Rectum | 75(68.2) | 15(13.6) | 10(9.1) | 9(8.2) | 1(0.9) |

RTOG, the Radiation Therapy Oncology Group; G, grade.
of rectum (see Table 3 and Figures 2A, 3A). According to the prediction models, $D_{1cm^3}$ was 70.29 (95%CI, 62.10–73.82) GyEQD2 and $D_{0.1cm^3}$ was 78.25 (95%CI, 51.26–84.92) GyEQD2 when the 1-year incidence of rectum morbidity with grade 1–4 was 10%. The 3-year incidence of rectum morbidity with grade 1–4 showed correlation with $D_{1cm^3}$ for rectum (see Table 3 and Figure 2B). According to the prediction models, $D_{1cm^3}$ was 54.80 (95%CI, 28.62–63.23) GyEQD2 when the 3-year incidence of rectum morbidity with grade 1–4 was 10%. The 1-year incidence of rectum morbidity with grade 2–4 showed correlation with $D_{1cm^3}$ and $D_{0.1cm^3}$ of rectum (see Table 3 and Figures 2C, 3B). According to the prediction models, $D_{1cm^3}$ was 74.18 (95%CI, 70.42–76.71) GyEQD2 and $D_{0.1cm^3}$ was 83.70 (95%CI, 74.53–90.82) GyEQD2 when the 1-year incidence of rectum morbidity with grade 2–4 was 10%. The 3-year incidence of rectum morbidity with grade 2–4 showed correlation with $D_{1cm^3}$ for rectum (see Table 3 and Figure 2D). According to the prediction models, $D_{1cm^3}$ was 66.37 (95%CI, 52.00–80.74) GyEQD2 when the 3-year incidence of rectum morbidity with grade 2–4 was 10%. The 5-year incidence of rectum morbidity with grade 2–4 showed correlation with $D_{1cm^3}$ of rectum (see Table 3 and Figure 2E). According to the prediction models, $D_{1cm^3}$ was 67.80 (95%CI, 58.12–71.11) GyEQD2 when the 3-year incidence of rectum morbidity with grade 2–4 was 10%. The 5-year incidence of rectum morbidity with grade 2–4 showed correlation with $D_{1cm^3}$ of rectum (see Table 3 and Figure 2F). According to the prediction models, $D_{1cm^3}$ was 66.37 (95%CI, 52.00–70.27) GyEQD2 when the 5-year incidence of rectum morbidity with grade 2–4 was 10%.

### Evaluating the Predictive Value of Toxicity Morbidity for the Dose of OARs

The receiver operating characteristic (ROC) curve was used to evaluate and compare the predictive values of $D_{1cm^3}$ and $D_{0.1cm^3}$ of rectum for rectum morbidity at 1, 3, 5 years, see Supplementary Figure S1. Table 4 showed the area under the curve (AUC) for the relationships between $D_{1cm^3}$, $D_{0.1cm^3}$ of rectum and the incidence of rectum morbidity. In addition, comparison of AUC for the prediction of rectum $D_{1cm^3}$ and rectum $D_{0.1cm^3}$ to 1-year incidence of rectum morbidity with grade 1–4 showed no statistically significant difference ($P = 0.338$), (see Table 4). Comparison of AUC for prediction of rectum $D_{1cm^3}$ and rectum $D_{0.1cm^3}$ to the 1-year incidence of rectum morbidity with grade 2–4 showed no statistically significant difference ($P = 0.083$) (see Table 5).

### DISCUSSION

LRC is regarded as a major late side effect in patients with locally advanced cervical cancer who underwent treatment with EBRT followed by brachytherapy boost (10). The International Commission on Radiation Units and Measurements (ICRU) reference point for rectum has been used as the standard dose specific point. Several studies have shown a positive correlation between the X-ray based ICRU rectal point dose and the occurrence of late rectal morbidity (2, 3). However, there is an enormous variation in the dose distribution in the adjacent OARs walls when using definitive radiotherapy with brachytherapy, and then the minimum dose in most of the irradiated tissue volumes: 0.1 cm$^3$, 1 cm$^3$, and 2 cm$^3$, namely $D_{0.1cm^3}$, $D_{1cm^3}$, $D_{2cm^3}$, were introduced for reporting the dose in the second GEC-ESTRO recommendations (11). Many researchers have reported that typical brachytherapy-related morbidities showed correlation

---

**Table 3** Probit model of relationships between $D_{2cm^3}$, $D_{1cm^3}$, $D_{0.1cm^3}$, $D_{ICRU}$ for rectum and incidence of rectum morbidity grade 1–4, 2–4 at 1, 3, 5 years.

| Parameter     | Time | Grade | $\beta$ [95%CI] | $Z$  | $P$  |
|---------------|------|-------|----------------|-----|-----|
| Rectum $D_{2cm^3}$ | 1 year | G 1–4 | -0.01 [-0.04, 0.04] | -0.17 | 0.865 |
|               |      | G 2–4 | -0.01 [-0.06, 0.03] | -0.69 | 0.493 |
|               | 3 year | G 1–4 | 0.01 [-0.05, 0.04] | 0.41 | 0.680 |
|               |      | G 2–4 | 0.01 [-0.05, 0.02] | -0.78 | 0.437 |
|               | 5 year | G 1–4 | 0.01 [-0.05, 0.04] | 0.21 | 0.835 |
|               |      | G 2–4 | -0.02 [-0.06, 0.02] | -0.88 | 0.381 |
| Rectum $D_{1cm^3}$ | 1 year | G 1–4 | 0.09 [0.03, 0.16] | 2.83 | 0.006 |
|               |      | G 2–4 | 0.17 [0.07, 0.27] | 3.24 | 0.001 |
|               | 3 year | G 1–4 | 0.05 [0.01, 0.10] | 2.09 | 0.037 |
|               |      | G 2–4 | 0.09 [0.03, 0.15] | 3.07 | 0.002 |
|               | 5 year | G 1–4 | 0.04 [-0.01, 0.08] | 1.66 | 0.096 |
|               |      | G 2–4 | 0.08 [0.02, 0.13] | 2.78 | 0.005 |
| Rectum $D_{0.1cm^3}$ | 1 year | G 1–4 | 0.05 [0.01, 0.10] | 2.19 | 0.029 |
|               |      | G 2–4 | 0.07 [0.01, 0.13] | 2.42 | 0.015 |
|               | 3 year | G 1–4 | 0.02 [-0.01, 0.05] | 1.18 | 0.240 |
|               |      | G 2–4 | 0.03 [-0.01, 0.07] | 1.44 | 0.150 |
|               | 5 year | G 1–4 | 0.01 [-0.02, 0.05] | 0.80 | 0.422 |
|               |      | G 2–4 | 0.02 [-0.02, 0.05] | 1.13 | 0.260 |
| Rectum $D_{ICRU}$ | 1 year | G 1–4 | -0.03 [-0.07, 0.02] | -1.17 | 0.241 |
|               |      | G 2–4 | -0.03 [-0.09, 0.02] | -1.19 | 0.232 |
|               | 3 year | G 1–4 | 0.01 [-0.03, 0.03] | 0.03 | 0.973 |
|               |      | G 2–4 | 0.01 [-0.02, 0.04] | 0.61 | 0.545 |
|               | 5 year | G 1–4 | 0.01 [-0.02, 0.04] | 0.41 | 0.683 |
|               |      | G 2–4 | 0.01 [-0.02, 0.05] | 0.85 | 0.396 |

$D_{2cm^3}$, $D_{1cm^3}$, $D_{0.1cm^3}$, minimal dose to the maximally exposed 2 cm$^3$, 1 cm$^3$, 0.1 cm$^3$ of organs at risk, respectively; $D_{ICRU}$, dose delivered to the International Commission for Radiation Units and Measurements (ICRU) point, G, grade.
FIGURE 2 | Probit models between incidence of rectum morbidity with different grade for rectum. (A) Probit models between 1-year incidence of rectum morbidity with grade 1–4 and $D_{1cm^3}$ for rectum; (B) Probit models between 3-year incidence of rectum morbidity with grade 1–4 and $D_{1cm^3}$ for rectum; (C) Probit models between 1-year incidence of rectum morbidity with grade 2–4 and $D_{1cm^3}$ for rectum; (D) Probit models between 3-year incidence of rectum morbidity grade 2–4 and $D_{1cm^3}$ for rectum; (E) Probit models between 5-year incidence of rectum morbidity with grade 2–4 and $D_{1cm^3}$ for rectum.

FIGURE 3 | Probit models between 1-year incidence of rectum morbidity and highlighted significant association of the $D_{0.1cm^3}$ for rectum. (A) Probit models between 1-year incidence of rectum morbidity with grade 1–4 and highlighted significant association of the $D_{0.1cm^3}$ for rectum; (B) Probit models between 1-year incidence of rectum morbidity with grade 2–4 and highlighted significant association of the $D_{0.1cm^3}$ for rectum.
with these small absolute volumes doses (12, 13). The dose–volume relationship for late rectal toxicity after IC/IS-BT has been systematically investigated before (14), but fewer studies have revealed the related outcomes of locally advanced cervical cancer treatment with IC/IS-BT. In the present study, the rectal D1cm³, D0.1cm³, D1cm³ and D2cm³ were calculated and the efficacy of these dose–volume histogram (DVH) parameters for predicting LRC in cervical carcinoma patients treated with definitive radiotherapy followed by IC/IS-BT were compared.

The prediction models between D2cm³, D1cm³, D0.1cm³, and DICRU for rectum and 1-year toxicity morbidity were established in this research. Consequently, positive dose–response relationships were observed between D1cm³ or D0.1cm³ and incidence of 1-year toxicity morbidity with grade 1–4, grade 2–4 LRC. Nevertheless, no positive dose–response relationships were observed between D2cm³, DICRU and with any grade incidence of LRC. This study also found that D1cm³ was predictive of a 3-year toxicity morbidity with grade 1–4 and grade 2–4 LRC, and 5-year toxicity morbidity with grade 2–4 LRC. Similarly, no positive dose–response relationships were observed between D2cm³, DICRU and with any grade incidence of LRC. Georg et al. (15) have found that the incidence of side effects of rectum was time-related; all rectal side effects have been developed within the first 2 years. Therefore, the incidence rates of LRC tended to stabilize during follow-up years 3–5. This meant that the incidence of rectal side effects was dynamically changed in short-term after treatment, while the DVH parameters remained constant. This might explain as to why different DVH parameters of rectum are considered as predictors for the incidence of rectal side effects during different time periods. It also concluded D1cm³ as a reliable indicator for predicting early and later grade 2–4 LRC.

Regarding the rectal DICRU hypothetical point determined by 2D image, it cannot directly represent the highest dose absorbed by the rectum (16). This explains that the resulting DICRU has very little for predicting the morbidity problem of rectum. D2cm³ showed a strong correlation for predicting the value of rectal D2cm³ dose with LRC (17, 18). Unfortunately, no correlation was observed in this research between D2cm³ and the incidence of 1-year with grade 1–4, grade 2–4 LRC, and even the incidence of 3/5year grade 1–4, grade 2–4 LRC. Nevertheless, the value of predicting late rectal toxicity for D2cm³ cannot be ignored or denied. The results obtained from several research studies (19) showed that D2cm³ was higher in patients with severe side effects. They also compared the severe side effects and mild adverse events by chi-square rather than Probit regression (in our study). But it became clear that high dose rectal D2cm³ could deteriorate LRC. In Mazeron et al. study (17), significant correlations were observed between rectal morbidity and D2cm³ and other DVH parameters by Probit model, which once again confirmed D2cm³ as an important predictive factor for LRC. Georg et al. (17) have demonstrated that the parameters D2cm³ and D1cm³ showed a good predictive value for rectal toxicity. Similarly, they enrolled 141 cervical cancer patients who received similar treatment regimen with us and evaluated the predictive value of rectal D2cm³, D1cm³, D0.1cm³, DICRU for LRC. In their research, significant differences of all DVH parameters and DICRU were observed between with and without LRC, but only D2cm³ and D1cm³ in major side effects were shown to be significantly higher than minor side effects. Furthermore, these studies also supported that high doses (>70–80 Gy) of D0.1cm³ might be associated with local effects such as ulceration, necrosis, and fistula, whereas intermediate doses (60–70 Gy), which was represented by D2cm³, would be associated with fibrosis, telangiectasis, or inflammation (20). It can be seen that both D2cm³ and D1cm³ are important indicators of LRC in locally advanced cervical cancer patients with IC/IS-BT. However, a clear association of D2cm³ with LRC was not found, and this might be due to limited number of patients and different scores in our work. Another reason for this is that the technique of IC/IS-BT might play an indispensable role. The EMBRACE (21) found a strong correlation between D2cm³ and D0.1cm³, but not for an individual at patient level, and the use of needles can cause a rectal wall hot spot and a major difference between D2cm³ and D0.1cm³. In our study, the patients enrolled underwent treatment with IC/IS-BT, which resulted D0.1cm³ as a better indicator that reflects the real hot spot distribution than the D2cm³ in patients who received IC/IS-BT.

Similarly, D0.1cm³ and D1cm³ were more sensitive for predicting the hot spot in the rectal wall. We observed that the D1cm³ was 74.18 (70.42–76.71) GyEQD2, 67.80 (58.12–71.11) GyEQD2, 66.37 (52.00–70.27) GyEQD2 when the 1-, 3-, and 5-year incidence of rectal morbidity with grade 2–4 was 10% based.

### TABLE 4 | AUC of incidence of rectum morbidity grade 1–4.

|                | AUC [95%CI]     | S.E.  | P       |
|----------------|-----------------|-------|---------|
| 1 year RectumD1cm³ | 0.75 [0.61, 0.89] | 0.07  | 0.002   |
| 3 years RectumD1cm³ | 0.71 [0.59, 0.84] | 0.06  | 0.010   |
| 5 years RectumD1cm³ | 0.61 [0.51, 0.73] | 0.06  | 0.041   |

AUC, area under the curve; D1cm³ and D0.1cm³, minimal dose to the maximally exposed 1 cm³, 0.1 cm³ of organs at risk, respectively.

### TABLE 5 | AUC of incidence of rectum morbidity grade 2–4.

|                | AUC [95%CI]     | S.E.  | P        |
|----------------|-----------------|-------|----------|
| 1 year RectumD1cm³ | 0.88 [0.81, 0.96] | 0.04  | <0.001   |
| 3 years RectumD1cm³ | 0.74 [0.61, 0.86] | 0.07  | 0.001    |
| 5 years RectumD1cm³ | 0.08 [0.02, 0.13] | 0.03  | 0.005    |
on the Probit model in our research. Thus, the patients with rectum $D_{1cm^3} > 66.37 - 74.18$ GyEQD2 should be closely observed for grade 2–4 late rectal morbidity.

This study has the following limitations: firstly, this was a single-center, retrospective study with a small sample size, and a multi-center study should be conducted in the future. Furthermore, most of the advanced-stage diseases in the European and American countries are treated with a definitive chemoradiation, but in our country, selective cases with stage IIB are treated with neoadjuvant chemotherapy followed by radical hysterectomy according to the 2019 NCCN guidelines (22) and ESMO Clinical Practice Guidelines (23). Nearly half of the patients received neo-adjuvant chemo with a hope to render them resectable in our research. Therefore, patients, who were still inoperable after receiving neoadjuvant chemotherapy, were transferred to our department to receive definitive radio(chemo) therapy. Further studies are needed to clarify whether treatment with neoadjuvant chemotherapy might influence the target dose delivery, the prognosis, and patient survival. Thirdly, contouring could not be performed, and planning based on MRI at each treatment session, as nearly 30% of treatments in our study received CT guided brachytherapy. The accuracy of OARs delineated based on CT images was less than that of MRI images. The reasons for these are due to the result of uncertainty of dose accurate evaluation.

CONCLUSION

$D_{1cm^3}$ and $D_{0.1cm^3}$ were considered as useful dosimetric parameters for predicting the risk of grade 1–4 LRC at 1 year, and $D_{1cm^3}$ might be an indicator for predicting 3–5 years LRC with grade 2–4. A rectal $D_{1cm^3}$ above 66.4 GyEQD2 may result in higher incidence of LRC > grade 2 using a Probit-type fitting.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

REFERENCES

1. Tanderup K, Eifel PJ, Yashar CM, Pötter R, Grigsby PW. Curative Radiation Therapy for Locally Advanced Cervical Cancer: Brachytherapy Is NOT Optional. Int J Radiat Oncol Biol Phys (2014) 88(3):537–9. doi: 10.1016/j.ijrobp.2013.11.011
2. Hyun Kim T, Choi J, Park SY, Lee SH, Lee KC, Yang DS, et al. Dosimetric Parameters That Predict Late Rectal Complications After Curative Radiotherapy in Patients With Uterine Cervical Carcinoma. Cancer (2005) 104(6):1304–11. doi: 10.1002/cncr.21292
3. Clark BG, Souhami L, Roman TN, Chappell R, Evans MD, Fowler JF. The Prediction of Late Rectal Complications in Patients Treated With High Dose-Rate Brachytherapy for Carcinoma of the Cervix. Int J Radiat Oncol Biol Phys (1997) 38(5):989–93. doi: 10.1016/s0360-3016(97)00074-6
4. Georg P, Lang S, Dimopoulos JC, Dörr W, Sturdza AE, Berger D, et al. Dose-Volume Histogram Parameters and Late Side Effects in Magnetic Resonance Image-Guided Adaptive Cervical Cancer Brachytherapy. Int J Radiat Oncol Biol Phys (2011) 79(2):356–62. doi: 10.1016/j.ijrobp.2009.11.002
5. Kato S, Tran DN, Ohno T, Nakano T, Kiyohara H, Ohkubo Y, et al. CT-Based 3D Dose-Volume Parameter of the Rectum and Late Rectal Complication in Patients With Cervical Cancer Treated With High-Dose-Rate Intracavitary Brachytherapy. J Radiat Res (2010) 51:215–21. doi: 10.1269/jrr.09118
6. Haie-Meder C, Pötter R, Van Limbergen E, Briot E, De Brabandere M, Dimopoulos J, et al. Recommendations From Gynaecological (GYN) GEC-ESTRO Working Group (I): Concepts and Terms in 3D Image Based 3D Treatment Planning in Cervix Cancer Brachytherapy With Emphasis on MRI Assessment of GTV and CTV. Radiother Oncol (2005) 74:235–45. doi: 10.1016/j.radonc.2004.12.015
7. Dimopoulos JC, Schard G, Berger D, Lang S, Goldner G, Helbich T, et al. Systematic Evaluation of MRI Findings in Different Stages of Treatment of Cervical Cancer: Potential of MRI on Delineation of Target, Pathoanatomic Structures, and Organs at Risk. Int J Radiat Oncol Biol Phys (2006) 64:1380–8. doi: 10.1016/j.ijrobp.2005.10.017

AUTHOR CONTRIBUTIONS

GC conceived of, designed, and supervised the study. NZ wrote the manuscript. YL, DH, and XG collected the data and analyzed the data. ZM and WY provided technical assistance with the study. All authors contributed to the article and approved the submitted version.

FUNDING

This work was partially supported by grants from the National Natural Science Foundation of China [grant numbers 82073331, 81201737, 31600679,81703034]; Project of Science and Technology Department of Jilin Province (grant number 20190303151SF); and Horizontal Project of Jilin University [grant numbers 2019YX435, 2019155].

ACKNOWLEDGMENTS

In writing this paper, I have benefited from the presence of the staff of the Departments of Radiology, Anesthesiology and Nursing team. They generously helped me collect materials and made many invaluable suggestions. I hereby extend my thanks to them for their kind help. Also, we thank Dr. Ning Wu, Dr. Mingyuan He and Dr. Hongfu Zhao for their help in this article.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.693864/full#supplementary-material
8. Cox JD, Stetz J, Pajak TF. Toxicity Criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys (1995) 31:1341–6. doi: 10.1016/0360-3016(95)00060-C.

9. Zhang N, Tang Y, Guo X, Mao Z, Yang W, Cheng G. Analysis of Dose-Effect Relationship Between DVH Parameters and Clinical Prognosis of Definitive Radio(Chemo)Therapy Combined With Intracavitary/Interstitial Brachytherapy in Patients With Locally Advanced Cervical Cancer: A Single-Center Retrospective Study. Brachytherapy (2020) 19:194–200. doi: 10.1016/j.brachy.2019.09.008.

10. Jensen NBK, Pöpper R, Kirchheiner K, Fokdal L, Lindegaard JC, Kirisits C, et al. Bowel Morbidity Following Radiochemotherapy and Image-Guided Adaptive Brachytherapy for Cervical Cancer: Physician- and Patient Reported Outcome From the EMBRACE Study. Radiother Oncol (2018) 127:431–9. doi: 10.1016/j.radonc.2018.05.016.

11. Pöpper R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, et al. Recommendations From Gynaecological (GYN) GEC ESTRO Working Group (II): Concepts and Terms in 3D Image-Based Treatment Planning in Cervix Cancer Brachytherapy-3D Dose Volume Parameters and Aspects of 3D Image-Based Anatomy, Radiation Physics, Radiobiology. Radiat Oncol (2006) 78:67–7. doi: 10.1016/j.radonc.2006.08.006.

12. Koom WS, Sohn DK, Kim JY, Kim JW, Shin KH, Yoon SH, et al. Computed Tomography-Based High-Dose-Rate Intracavitary Brachytherapy for Uterine Cervical Cancer: Preliminary Demonstration of Correlation Between Dose-Volume Parameters and Rectal Mucosal Changes Observed by Flexible Sigmoidoscopy. Int J Radiat Oncol Biol Phys (2007) 68:1446–54. doi: 10.1016/j.ijrobp.2007.02.009.

13. Dang YZ, Li P, Li JP, Bai F, Zhang Y, Mu YF, et al. The Efficacy and Late Toxicities of Computed Tomography-Based Brachytherapy With Intracavitary and Interstitial Technique in Advanced Cervical Cancer. J Cancer (2018) 18:1635–41. doi: 10.7150/jca.23974.

14. Kim Y, Kim YJ, Kim YJ, Lim YK, Jeong C, Jeong J, et al. Toxicities and Dose-Volume Histogram Parameters of MRI-Based Brachytherapy for Cervical Cancer. Brachytherapy (2017) 16:116–25. doi: 10.1016/j.brachy.2016.10.005.

15. Georg P, Boni A, Ghabous A, Goldner G, Schmid MP, Georg D, et al. Time Course of Late Rectal- and Urinary Bladder Side Effects After MRI-Guided Adaptive Brachytherapy for Cervical Cancer. Strahlenther Onkol (2013) 189:535–40. doi: 10.1007/s00061-013-0365-7.

16. Wachter-Gerstner N, Wachter S, Reinstadler E, Fellner C, Knocke TH, Wambersie A, et al. Bladder and Rectum Dose Defined From MRI Based Treatment Planning for Cervix Cancer Brachytherapy: Comparison of Dose-Volume Histograms for Organ Contours and Organ Wall, Comparison With ICRU Rectum and Bladder Reference Point. Radiother Oncol (2003) 68:269–76. doi: 10.1016/s0167-8140(03)00189-0.

17. Mazeron R, Fokdal LU, Kirchheiner K, Georg P, Jastanayih N, Segerid B, et al. Dose-Volume Effect Relationships for Late Rectal Morbidity in Patients Treated With Chemoradiation and MRI-Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: Results From the Prospective Multicenter EMBRACE Study. Radiother Oncol (2016) 120:412–9. doi: 10.1016/j.radonc.2016.06.006.

18. Chopra S, Dora T, Engineer R, Mechanery S, Agarwal P, Kannan S, et al. Late Rectal Toxicity After Image-Based High-Dose-Rate Interstitial Brachytherapy for Postoperative Recurrent and/or Residual Cervical Cancers: EQD2 Predictors for Grade ≥II Toxicity. Brachytherapy (2015) 14:881–8. doi: 10.1016/j.brachy.2015.08.007.

19. Lee LJ, Viswanathan AN. Predictors of Toxicity After Image-Guided High-Dose-Rate Interstitial Brachytherapy for Gynecologic Cancer. Int J Radiat Oncol Biol Phys (2012) 84:1192–7. doi: 10.1016/j.ijrobp.2012.01.085.

20. Georg P, Kirisits C, Goldner G, Dör R, Hammer J, Pötzi R, et al. Correlation of Dose-Volume Parameters, Endoscopic and Clinical Rectal Side Effects in Cervix Cancer Patients Treated With Definitive Radiotherapy Including MRI-Based Brachytherapy. Radiother Oncol (2009) 91:173–80. doi: 10.1016/j.radonc.2009.02.008.

21. Embrace. An International Study on MRI-Guided Brachytherapy in Locally Advanced Cervical Cancer. Available at: https://www.embracestudy.dk/.

22. Koh WI, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, et al. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2019) 17:64–84. doi: 10.6004/jnccn.2019.0001.

23. Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N. ESMO Guidelines Committee. Cervical Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol (2017) 28:72–83. doi: 10.1093/annonc/mdx220.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Zhang, Liu, Han, Guo, Mao, Yang and Cheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.